TABLE OF CONTENT

REMERCIEMENTS ***1***

ABBREVIATIONS ***7***

SUMMARY ***9***

RESUME ***13***

INTRODUCTION ***17***

1. Lung cancer 18
   - 1.1. Epidemiology and risk factors 18
   - 1.2. Clinical manifestations 20
   - 1.3. Classification and pathology 20
   - 1.4. Non-small cell lung carcinoma 22
   - 1.5. Small cell lung carcinoma 40
   - 1.6. Reasons for treatment failure 43
   - 1.7. Strategies and new perspectives 44
2. Cisplatin, Carboplatin and Paclitaxel 46
   - 2.1. Cisplatin and carboplatin 46
   - 2.2. Paclitaxel 52
   - 2.3. Cisplatin, carboplatin and paclitaxel related toxicities 53
3. Inhaled therapy as a loco-regional treatment against lung cancers 66
   - 3.1. The lungs 66
   - 3.2. Drug delivery to the lungs 71
   - 3.3. Pulmonary route for lung cancer treatment 81

SCIENTIFIC STRATEGY AND MAIN OBJECTIVES ***89***

EXPERIMENTAL PART ***94***

Part I: Optimization of cisplatin-based DPI formulation with controlled-release and lung-retention properties ***95***

1. Introduction and aims 96
2. Materials and methods 97
   - 2.1. Materials 97
   - 2.2. Safety procedures 98
   - 2.3. Preliminary studies on CIS-DPI-TS 98

2.4. Preparation and *in vitro* evaluation of new cisplatin DPIs 107
2.5. Statistical analyses 112
3. Results and discussion 112
3.1. Preliminary studies on CIS-DPI-TS 112
3.2. Optimization of the cisplatin-based DPI formulation with controlled cisplatin-release and lung-retention properties 122
4. Conclusion 138

Part II: Selection of the most appropriate CIS-DPI-50 monotherapy regimen..139

1. Introduction and aims 140
2. Materials and methods 140
2.1. Materials 140
2.2. *In vivo* studies 141
2.3. Development of Lewis lung carcinoma expressing luciferase model 141
2.4. PK study on LLC1-*Luc* grafted mice 141
2.5. Biodistribution of CIS-DPI-50 and immunohistochemistry labelling following the administration of different regimens 142
2.6. Efficacy study on M109-HiFR-*Luc*2 lung carcinoma model 145
2.7. Statistical analyses 145
3. Results and discussion 146
3.1. PK study of CIS-DPI-50 on Lewis lung carcinoma grafted mice 146
3.2. Selection of the most appropriate CIS-DPI-50 monotherapy regimen 152
3.3. Efficacy study 166
4. Conclusion 170

Part III: Evaluation of the combination of CIS-DPI-50 and IV cisplatin-based platinum doublet..... 171

1. Introduction and aims 172
2. Material and methods 173
2.1. Materials 173
2.2. CIS-DPI-50 formulation production and characterization (DPI-0.5 and DPI-1) 173
2.3. *In vivo* toxicity studies 173
2.4. Efficacy study 179
2.5. Statistical analyses 180
3. Results and discussion 181
3.1. Overall tolerance 181
3.2. Pulmonary tolerance assessment of CIS-DPI-50, CIS-IV and their combinations 182
3.3. Renal tolerance assessment of CIS-DPI-50, CIS-IV and their combinations 193
3.4. Conclusions for pulmonary and renal tolerance 203
3.5. Efficacy evaluation on the M109-HiFR-*Luc2* lung carcinoma orthotopic model in mice 203
4. Conclusion 207

Part IV: Evaluation of the tolerance of the combination of CIS-DPI-50 and IV carboplatin-based platinum doublet..... 209

1. Introduction and aims 210

2. Materials and methods 211

2.1. Materials..... 211
2.2. *In vivo* toxicity studies 211
2.3. Formulation and administration for *in vivo* experiments..... 211
2.4. Regimen administration 212
2.5. Pulmonary tolerance evaluation..... 214
2.6. Renal tolerance evaluation..... 214
2.7. Myelosuppression evaluation 214
2.8. Statistical analyses..... 215

3. Results 215

3.1. Determination of maximum tolerated dose for CIS-DPI-50 and IV-CARB-PTX 215
3.2. Tolerance of DPI-0.5, IV-CARB-PTX and their combinations 217
3.3. Body weight profiles and general evaluation..... 217
3.4. Evaluation of pulmonary toxicity..... 218
3.5. Evaluation of nephrotoxicity 225
3.6. Evaluation of myelotoxicity..... 226

4. Discussion..... 231

5. Conclusion 239

GENERAL CONCLUSIONS AND PERSPECTIVES 241

BIBLIOGRAPHY 248

APPENDIX 267

1. Abstract and Poster at Drug Delivery to the Lungs (DDL, 29) Conference, Edinburgh, Scotland, UK. December 12-14, 2018..... 268

2. Abstract and Poster at 12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology 270

3. Abstract and Poster at Respiratory Drug Delivery (RDD, 20) Conference, DIGITAL, 2020 .. 272

4. Abstract for an oral presentation at Congrès de la Société Francophone de Néphrologie, Dialyse et Transplantation (SFNDT), DIGITAL, October 7-8 2020..... 274

5. Article 1: Pulmonary and renal tolerance of cisplatin-based regimens combining intravenous and endotracheal routes for lung cancer treatment in mice 277

6. Article 2: The combination of an innovative dry powder for inhalation and a standard cisplatin-based chemotherapy in view of therapeutics intensification against lung tumours 278

7. Article 3: Preclinical tolerance evaluation of the addition of a cisplatin-based dry powder for inhalation to the conventional carboplatin-paclitaxel doublet for the treatment of non-small cell lung cancer..... 279